 David Fleischer
Concepts (429)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peanut Hypersensitivity | 54 | 2023 | 197 | 12.940 |
Why?
| | Arachis | 41 | 2023 | 146 | 9.180 |
Why?
| | Food Hypersensitivity | 43 | 2023 | 253 | 8.640 |
Why?
| | Allergens | 46 | 2023 | 413 | 7.620 |
Why?
| | Desensitization, Immunologic | 26 | 2023 | 117 | 5.460 |
Why?
| | Infant Nutritional Physiological Phenomena | 11 | 2019 | 133 | 2.920 |
Why?
| | Diet | 15 | 2022 | 1080 | 2.250 |
Why?
| | Immunoglobulin E | 27 | 2023 | 316 | 1.700 |
Why?
| | Anaphylaxis | 10 | 2023 | 148 | 1.610 |
Why?
| | Eosinophilic Esophagitis | 10 | 2021 | 296 | 1.560 |
Why?
| | Dermatitis, Atopic | 12 | 2021 | 307 | 1.550 |
Why?
| | Transdermal Patch | 3 | 2020 | 15 | 1.540 |
Why?
| | Milk Hypersensitivity | 6 | 2023 | 22 | 1.390 |
Why?
| | Skin Tests | 19 | 2023 | 122 | 1.380 |
Why?
| | Immunotherapy | 8 | 2023 | 475 | 1.230 |
Why?
| | Primary Prevention | 5 | 2022 | 172 | 1.200 |
Why?
| | Esophagoscopy | 11 | 2022 | 184 | 1.160 |
Why?
| | Gastrointestinal Diseases | 9 | 2019 | 183 | 1.030 |
Why?
| | Plant Proteins | 3 | 2022 | 81 | 1.030 |
Why?
| | Infant | 39 | 2023 | 7935 | 1.020 |
Why?
| | Egg Hypersensitivity | 11 | 2019 | 45 | 1.000 |
Why?
| | Infant Formula | 4 | 2023 | 74 | 0.990 |
Why?
| | Humans | 146 | 2023 | 114756 | 0.960 |
Why?
| | Breast Feeding | 8 | 2023 | 370 | 0.910 |
Why?
| | Nut Hypersensitivity | 3 | 2010 | 9 | 0.900 |
Why?
| | Noncommunicable Diseases | 1 | 2023 | 14 | 0.880 |
Why?
| | Child | 51 | 2023 | 18352 | 0.880 |
Why?
| | Protein Hydrolysates | 3 | 2018 | 7 | 0.830 |
Why?
| | Eczema | 10 | 2022 | 81 | 0.790 |
Why?
| | Hypersensitivity, Immediate | 3 | 2023 | 46 | 0.780 |
Why?
| | Administration, Cutaneous | 7 | 2023 | 117 | 0.780 |
Why?
| | Endoscopy, Gastrointestinal | 7 | 2022 | 204 | 0.770 |
Why?
| | Child, Preschool | 30 | 2023 | 9079 | 0.760 |
Why?
| | Immune Tolerance | 9 | 2023 | 328 | 0.750 |
Why?
| | Schools | 4 | 2021 | 399 | 0.650 |
Why?
| | Antigens, Plant | 5 | 2022 | 47 | 0.650 |
Why?
| | Esophageal Stenosis | 5 | 2014 | 44 | 0.650 |
Why?
| | Asthma | 8 | 2021 | 2032 | 0.610 |
Why?
| | Female | 62 | 2023 | 59507 | 0.600 |
Why?
| | Esophageal Neoplasms | 8 | 2022 | 273 | 0.560 |
Why?
| | Double-Blind Method | 12 | 2023 | 1662 | 0.550 |
Why?
| | Eosinophilia | 4 | 2013 | 186 | 0.530 |
Why?
| | Gastroenterology | 2 | 2015 | 159 | 0.530 |
Why?
| | Administration, Oral | 9 | 2022 | 731 | 0.520 |
Why?
| | Practice Guidelines as Topic | 9 | 2021 | 1393 | 0.500 |
Why?
| | Male | 53 | 2020 | 55579 | 0.490 |
Why?
| | Pneumonia, Viral | 4 | 2020 | 340 | 0.490 |
Why?
| | Coronavirus Infections | 4 | 2020 | 332 | 0.490 |
Why?
| | Lye | 1 | 2014 | 1 | 0.480 |
Why?
| | Caustics | 1 | 2014 | 7 | 0.470 |
Why?
| | Dilatation | 2 | 2014 | 60 | 0.470 |
Why?
| | Endosonography | 1 | 2015 | 140 | 0.460 |
Why?
| | Burns, Chemical | 1 | 2014 | 25 | 0.460 |
Why?
| | Feeding Behavior | 3 | 2019 | 574 | 0.450 |
Why?
| | Barrett Esophagus | 3 | 2022 | 147 | 0.440 |
Why?
| | Environmental Exposure | 1 | 2017 | 374 | 0.440 |
Why?
| | Betacoronavirus | 3 | 2020 | 252 | 0.430 |
Why?
| | Pandemics | 5 | 2020 | 1319 | 0.420 |
Why?
| | Gastrointestinal Hemorrhage | 4 | 2007 | 102 | 0.400 |
Why?
| | Adolescent | 22 | 2020 | 17808 | 0.390 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2020 | 1214 | 0.390 |
Why?
| | Infant Food | 2 | 2023 | 63 | 0.370 |
Why?
| | United States | 23 | 2020 | 12176 | 0.360 |
Why?
| | Adenocarcinoma | 5 | 2022 | 801 | 0.360 |
Why?
| | Allergy and Immunology | 3 | 2020 | 51 | 0.360 |
Why?
| | Esophagus | 8 | 2019 | 226 | 0.360 |
Why?
| | Food | 4 | 2022 | 160 | 0.350 |
Why?
| | Allergists | 3 | 2020 | 19 | 0.340 |
Why?
| | Anti-Allergic Agents | 3 | 2015 | 41 | 0.340 |
Why?
| | Virtual Reality | 2 | 2021 | 38 | 0.340 |
Why?
| | Consensus | 6 | 2023 | 535 | 0.330 |
Why?
| | Cattle | 3 | 2023 | 921 | 0.330 |
Why?
| | Risk | 5 | 2018 | 815 | 0.320 |
Why?
| | Epinephrine | 3 | 2021 | 164 | 0.300 |
Why?
| | Capsule Endoscopy | 1 | 2007 | 17 | 0.290 |
Why?
| | Severity of Illness Index | 6 | 2019 | 2539 | 0.290 |
Why?
| | Intestinal Diseases | 1 | 2007 | 33 | 0.290 |
Why?
| | Treatment Outcome | 9 | 2020 | 9089 | 0.290 |
Why?
| | Colonoscopy | 4 | 2014 | 205 | 0.290 |
Why?
| | Milk Proteins | 2 | 2018 | 36 | 0.290 |
Why?
| | Time Factors | 7 | 2020 | 6124 | 0.280 |
Why?
| | Enterocolitis | 2 | 2020 | 33 | 0.270 |
Why?
| | Brazil | 2 | 2023 | 90 | 0.270 |
Why?
| | Adrenal Cortex Hormones | 3 | 2017 | 498 | 0.270 |
Why?
| | Endoscopy | 6 | 2018 | 248 | 0.270 |
Why?
| | Capsules | 2 | 2005 | 36 | 0.260 |
Why?
| | Rhinitis, Allergic | 3 | 2022 | 35 | 0.260 |
Why?
| | National Institute of Allergy and Infectious Diseases (U.S.) | 7 | 2019 | 28 | 0.250 |
Why?
| | Canada | 3 | 2020 | 322 | 0.240 |
Why?
| | Age Factors | 7 | 2018 | 2890 | 0.240 |
Why?
| | Administration, Sublingual | 3 | 2016 | 13 | 0.240 |
Why?
| | Follow-Up Studies | 7 | 2020 | 4420 | 0.240 |
Why?
| | Immunomodulation | 2 | 2018 | 84 | 0.240 |
Why?
| | Pregnancy | 8 | 2022 | 5525 | 0.240 |
Why?
| | Gastrointestinal Neoplasms | 3 | 2000 | 59 | 0.240 |
Why?
| | Diagnostic Imaging | 2 | 2006 | 275 | 0.220 |
Why?
| | Eosinophils | 2 | 2018 | 278 | 0.220 |
Why?
| | Laser Therapy | 5 | 1985 | 100 | 0.220 |
Why?
| | Intestinal Mucosa | 2 | 2015 | 530 | 0.220 |
Why?
| | Young Adult | 10 | 2020 | 10463 | 0.210 |
Why?
| | Predictive Value of Tests | 3 | 2020 | 1796 | 0.200 |
Why?
| | Food Analysis | 1 | 2022 | 18 | 0.200 |
Why?
| | Point-of-Care Testing | 1 | 2022 | 29 | 0.190 |
Why?
| | Adult | 18 | 2020 | 30548 | 0.190 |
Why?
| | Gastroesophageal Reflux | 2 | 2022 | 234 | 0.190 |
Why?
| | Child Day Care Centers | 1 | 2021 | 33 | 0.190 |
Why?
| | Aptamers, Nucleotide | 1 | 2022 | 73 | 0.190 |
Why?
| | Milk | 3 | 2018 | 124 | 0.190 |
Why?
| | Dietary Exposure | 1 | 2020 | 7 | 0.180 |
Why?
| | Restaurants | 1 | 2020 | 16 | 0.180 |
Why?
| | Diet Therapy | 2 | 2017 | 36 | 0.180 |
Why?
| | Animals | 11 | 2023 | 31761 | 0.180 |
Why?
| | Deglutition Disorders | 2 | 2019 | 119 | 0.180 |
Why?
| | Infusions, Subcutaneous | 1 | 2020 | 19 | 0.180 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2020 | 82 | 0.180 |
Why?
| | Eggs | 2 | 2018 | 30 | 0.180 |
Why?
| | Quality of Life | 6 | 2022 | 2358 | 0.170 |
Why?
| | Diagnosis, Differential | 3 | 2015 | 1340 | 0.170 |
Why?
| | Europe | 2 | 2022 | 336 | 0.170 |
Why?
| | Inservice Training | 1 | 2020 | 105 | 0.170 |
Why?
| | Healthy Volunteers | 1 | 2020 | 197 | 0.170 |
Why?
| | Immunization | 3 | 2017 | 401 | 0.160 |
Why?
| | United Kingdom | 4 | 2020 | 226 | 0.160 |
Why?
| | Hypersensitivity | 2 | 2020 | 254 | 0.160 |
Why?
| | Multiphasic Screening | 1 | 2018 | 2 | 0.160 |
Why?
| | Meta-Analysis as Topic | 2 | 2016 | 161 | 0.150 |
Why?
| | Confidence Intervals | 1 | 2019 | 309 | 0.150 |
Why?
| | Ambulatory Care Facilities | 1 | 2020 | 212 | 0.150 |
Why?
| | Population Groups | 1 | 2018 | 57 | 0.150 |
Why?
| | Telemedicine | 3 | 2020 | 663 | 0.150 |
Why?
| | Coal Tar | 1 | 2017 | 2 | 0.150 |
Why?
| | Phosphodiesterase 4 Inhibitors | 1 | 2017 | 2 | 0.150 |
Why?
| | Skin Cream | 1 | 2017 | 7 | 0.150 |
Why?
| | Keratolytic Agents | 1 | 2017 | 5 | 0.150 |
Why?
| | Food, Genetically Modified | 1 | 2017 | 3 | 0.150 |
Why?
| | Emollients | 1 | 2017 | 11 | 0.150 |
Why?
| | Baths | 1 | 2017 | 17 | 0.150 |
Why?
| | Plants, Genetically Modified | 1 | 2017 | 18 | 0.150 |
Why?
| | Histamine Antagonists | 1 | 2017 | 20 | 0.150 |
Why?
| | Monitoring, Physiologic | 2 | 1990 | 248 | 0.150 |
Why?
| | Clothing | 1 | 2017 | 19 | 0.150 |
Why?
| | School Health Services | 1 | 2020 | 206 | 0.150 |
Why?
| | Crops, Agricultural | 1 | 2017 | 28 | 0.150 |
Why?
| | Mothers | 1 | 2023 | 651 | 0.140 |
Why?
| | Prognosis | 2 | 2020 | 3334 | 0.140 |
Why?
| | Calcineurin Inhibitors | 1 | 2017 | 58 | 0.140 |
Why?
| | Risk Assessment | 4 | 2019 | 2973 | 0.140 |
Why?
| | Palliative Care | 4 | 2010 | 641 | 0.140 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2022 | 452 | 0.140 |
Why?
| | Kidney Transplantation | 1 | 2022 | 541 | 0.140 |
Why?
| | Nutritionists | 1 | 2016 | 13 | 0.140 |
Why?
| | Eating | 1 | 2019 | 345 | 0.130 |
Why?
| | Decision Support Techniques | 1 | 2020 | 351 | 0.130 |
Why?
| | Education, Medical, Continuing | 1 | 2017 | 118 | 0.130 |
Why?
| | Basophils | 2 | 2015 | 64 | 0.130 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2017 | 97 | 0.130 |
Why?
| | Bottle Feeding | 1 | 2016 | 20 | 0.130 |
Why?
| | Prevalence | 3 | 2017 | 2249 | 0.130 |
Why?
| | Biological Products | 1 | 2018 | 167 | 0.130 |
Why?
| | Indonesia | 1 | 2015 | 18 | 0.130 |
Why?
| | Membrane Proteins | 1 | 2022 | 1022 | 0.130 |
Why?
| | Health Care Reform | 2 | 1994 | 92 | 0.130 |
Why?
| | Aging | 1 | 2005 | 1620 | 0.130 |
Why?
| | Catheter Ablation | 1 | 2019 | 291 | 0.130 |
Why?
| | Nutritional Requirements | 1 | 2016 | 75 | 0.130 |
Why?
| | Natural Orifice Endoscopic Surgery | 1 | 2015 | 26 | 0.120 |
Why?
| | Omalizumab | 1 | 2015 | 45 | 0.120 |
Why?
| | Anti-Bacterial Agents | 3 | 2017 | 1477 | 0.120 |
Why?
| | Sublingual Immunotherapy | 1 | 2015 | 7 | 0.120 |
Why?
| | Probiotics | 1 | 2015 | 46 | 0.120 |
Why?
| | Guideline Adherence | 1 | 2019 | 490 | 0.120 |
Why?
| | Caregivers | 2 | 2020 | 717 | 0.120 |
Why?
| | History, 21st Century | 1 | 2015 | 160 | 0.120 |
Why?
| | Fluticasone | 1 | 2015 | 87 | 0.120 |
Why?
| | Middle Aged | 15 | 2019 | 26757 | 0.120 |
Why?
| | History, 20th Century | 1 | 2015 | 265 | 0.120 |
Why?
| | Risk Factors | 6 | 2019 | 8627 | 0.120 |
Why?
| | Surveys and Questionnaires | 6 | 2022 | 4625 | 0.110 |
Why?
| | Biopsy | 5 | 2019 | 1040 | 0.110 |
Why?
| | Physicians | 2 | 2020 | 772 | 0.110 |
Why?
| | Family | 2 | 2015 | 591 | 0.110 |
Why?
| | Infant, Newborn | 5 | 2019 | 5035 | 0.110 |
Why?
| | Premedication | 3 | 1990 | 36 | 0.110 |
Why?
| | Wrist Injuries | 1 | 2014 | 25 | 0.110 |
Why?
| | Cumulative Trauma Disorders | 1 | 2014 | 29 | 0.110 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 545 | 0.110 |
Why?
| | Wrist Joint | 1 | 2014 | 59 | 0.110 |
Why?
| | Patient Education as Topic | 2 | 2015 | 679 | 0.110 |
Why?
| | Posture | 2 | 2014 | 153 | 0.110 |
Why?
| | Societies, Medical | 2 | 1994 | 663 | 0.110 |
Why?
| | Delivery of Health Care | 1 | 2020 | 833 | 0.110 |
Why?
| | Occupational Injuries | 1 | 2014 | 46 | 0.110 |
Why?
| | Information Systems | 1 | 1993 | 61 | 0.110 |
Why?
| | Evidence-Based Medicine | 1 | 2017 | 667 | 0.110 |
Why?
| | Prospective Studies | 7 | 2019 | 6217 | 0.110 |
Why?
| | Mucositis | 1 | 2012 | 18 | 0.100 |
Why?
| | Sympathomimetics | 1 | 2012 | 25 | 0.100 |
Why?
| | Cohort Studies | 5 | 2022 | 4901 | 0.100 |
Why?
| | Poisson Distribution | 1 | 2012 | 72 | 0.100 |
Why?
| | Biomarkers | 2 | 2020 | 3416 | 0.100 |
Why?
| | Patient Compliance | 2 | 2016 | 525 | 0.100 |
Why?
| | Child Development | 1 | 2016 | 387 | 0.100 |
Why?
| | Pregnenediones | 1 | 2012 | 21 | 0.100 |
Why?
| | Oximetry | 2 | 1990 | 81 | 0.100 |
Why?
| | Bacterial Proteins | 1 | 2017 | 739 | 0.100 |
Why?
| | Self Care | 1 | 2014 | 350 | 0.100 |
Why?
| | Curriculum | 1 | 2017 | 825 | 0.100 |
Why?
| | Patient Satisfaction | 1 | 2015 | 583 | 0.100 |
Why?
| | Stents | 3 | 2000 | 475 | 0.090 |
Why?
| | Recurrence | 2 | 2004 | 936 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 1 | 2019 | 1178 | 0.090 |
Why?
| | Symptom Assessment | 1 | 2012 | 119 | 0.090 |
Why?
| | Feeding and Eating Disorders of Childhood | 1 | 2010 | 6 | 0.090 |
Why?
| | Metaplasia | 2 | 2022 | 54 | 0.090 |
Why?
| | Disease Progression | 4 | 2019 | 2387 | 0.090 |
Why?
| | Phenotype | 1 | 2018 | 2812 | 0.090 |
Why?
| | Adaptation, Psychological | 1 | 2015 | 547 | 0.090 |
Why?
| | Health Surveys | 1 | 2012 | 443 | 0.090 |
Why?
| | Health Policy | 1 | 1993 | 334 | 0.090 |
Why?
| | Immunoassay | 1 | 2010 | 95 | 0.090 |
Why?
| | Flavoring Agents | 1 | 1990 | 6 | 0.090 |
Why?
| | Cathartics | 1 | 1990 | 11 | 0.090 |
Why?
| | Epithelial Cells | 2 | 2014 | 955 | 0.090 |
Why?
| | Citrates | 1 | 1990 | 43 | 0.090 |
Why?
| | Immunologic Factors | 2 | 2022 | 220 | 0.090 |
Why?
| | Coloring Agents | 1 | 1990 | 72 | 0.080 |
Why?
| | Regression Analysis | 1 | 2012 | 946 | 0.080 |
Why?
| | Duodenoscopy | 1 | 1989 | 7 | 0.080 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2013 | 283 | 0.080 |
Why?
| | Gastroscopy | 1 | 1989 | 18 | 0.080 |
Why?
| | Drainage | 1 | 2010 | 151 | 0.080 |
Why?
| | Food, Formulated | 1 | 2009 | 14 | 0.080 |
Why?
| | Maternal Exposure | 1 | 2010 | 138 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2013 | 664 | 0.080 |
Why?
| | Physician-Patient Relations | 1 | 1993 | 462 | 0.080 |
Why?
| | Lasers | 3 | 1985 | 121 | 0.080 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1134 | 0.080 |
Why?
| | Light Coagulation | 1 | 1988 | 7 | 0.080 |
Why?
| | Hypnotics and Sedatives | 1 | 1989 | 134 | 0.080 |
Why?
| | Physical Examination | 1 | 2009 | 220 | 0.070 |
Why?
| | Feces | 1 | 1990 | 374 | 0.070 |
Why?
| | Precancerous Conditions | 2 | 2019 | 158 | 0.070 |
Why?
| | Antibodies, Monoclonal | 1 | 2013 | 1270 | 0.070 |
Why?
| | Cholestasis | 1 | 2010 | 224 | 0.070 |
Why?
| | Retrospective Studies | 5 | 2022 | 12515 | 0.070 |
Why?
| | Risk Reduction Behavior | 2 | 2019 | 201 | 0.070 |
Why?
| | Sepsis | 2 | 1989 | 508 | 0.070 |
Why?
| | Immunologic Tests | 1 | 2005 | 16 | 0.060 |
Why?
| | Remission, Spontaneous | 1 | 2005 | 37 | 0.060 |
Why?
| | Aged | 13 | 2019 | 19094 | 0.060 |
Why?
| | Sensitivity and Specificity | 3 | 2022 | 1691 | 0.060 |
Why?
| | Equipment Safety | 1 | 2005 | 39 | 0.060 |
Why?
| | Anti-Inflammatory Agents | 1 | 2009 | 450 | 0.060 |
Why?
| | Equipment Design | 2 | 2005 | 508 | 0.060 |
Why?
| | Dietetics | 2 | 2017 | 22 | 0.060 |
Why?
| | Immunoglobulin G | 3 | 2014 | 774 | 0.060 |
Why?
| | Esophageal and Gastric Varices | 1 | 1985 | 31 | 0.060 |
Why?
| | Procainamide | 1 | 1984 | 5 | 0.060 |
Why?
| | Hyperplasia | 2 | 2022 | 163 | 0.060 |
Why?
| | Therapeutic Irrigation | 1 | 1984 | 67 | 0.060 |
Why?
| | Pollen | 1 | 2023 | 24 | 0.060 |
Why?
| | Intestinal Absorption | 1 | 1984 | 93 | 0.060 |
Why?
| | Software | 1 | 2007 | 536 | 0.060 |
Why?
| | Epitopes | 1 | 2005 | 435 | 0.050 |
Why?
| | Excipients | 1 | 2023 | 49 | 0.050 |
Why?
| | Disease Management | 2 | 2019 | 560 | 0.050 |
Why?
| | Turkey | 1 | 2022 | 15 | 0.050 |
Why?
| | Metals | 2 | 2000 | 107 | 0.050 |
Why?
| | Immunity | 1 | 2023 | 121 | 0.050 |
Why?
| | Disease Models, Animal | 1 | 2011 | 3542 | 0.050 |
Why?
| | HLA Antigens | 1 | 2022 | 224 | 0.050 |
Why?
| | Injections | 1 | 2021 | 159 | 0.040 |
Why?
| | Adrenergic alpha-Agonists | 1 | 2020 | 29 | 0.040 |
Why?
| | Japan | 1 | 2000 | 87 | 0.040 |
Why?
| | Respiratory Sounds | 1 | 2021 | 111 | 0.040 |
Why?
| | Educational Personnel | 1 | 2020 | 13 | 0.040 |
Why?
| | Terbutaline | 1 | 2020 | 8 | 0.040 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2000 | 18 | 0.040 |
Why?
| | China | 1 | 2000 | 162 | 0.040 |
Why?
| | Cholestasis, Intrahepatic | 1 | 2000 | 39 | 0.040 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2020 | 61 | 0.040 |
Why?
| | Albuterol | 1 | 2020 | 102 | 0.040 |
Why?
| | Food Contamination | 1 | 2019 | 43 | 0.040 |
Why?
| | Bronchodilator Agents | 1 | 2021 | 240 | 0.040 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2018 | 76 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 2 | 2012 | 493 | 0.040 |
Why?
| | Medical History Taking | 1 | 2019 | 114 | 0.040 |
Why?
| | Esophagogastric Junction | 1 | 2019 | 42 | 0.040 |
Why?
| | Psychometrics | 1 | 2022 | 607 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2099 | 0.040 |
Why?
| | Health Planning Guidelines | 1 | 2018 | 25 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2021 | 296 | 0.040 |
Why?
| | New Zealand | 1 | 2018 | 41 | 0.040 |
Why?
| | Efferent Pathways | 1 | 1998 | 16 | 0.040 |
Why?
| | Hydrolysis | 1 | 2018 | 175 | 0.040 |
Why?
| | Locus Coeruleus | 1 | 1998 | 19 | 0.040 |
Why?
| | Food Labeling | 1 | 2017 | 17 | 0.040 |
Why?
| | Markov Chains | 1 | 2018 | 114 | 0.040 |
Why?
| | RNA, Viral | 1 | 2021 | 566 | 0.040 |
Why?
| | Early Medical Intervention | 1 | 2018 | 51 | 0.040 |
Why?
| | Cross Reactions | 1 | 2017 | 117 | 0.040 |
Why?
| | Immune Sera | 1 | 2017 | 79 | 0.040 |
Why?
| | Endoscopy, Digestive System | 1 | 2019 | 110 | 0.040 |
Why?
| | Australia | 1 | 2018 | 207 | 0.040 |
Why?
| | Skin Irritancy Tests | 1 | 2017 | 3 | 0.040 |
Why?
| | Health Care Surveys | 1 | 2019 | 539 | 0.040 |
Why?
| | Uncertainty | 1 | 2017 | 96 | 0.040 |
Why?
| | Societies, Scientific | 1 | 2017 | 47 | 0.040 |
Why?
| | Norepinephrine | 1 | 1998 | 200 | 0.030 |
Why?
| | Antibody Specificity | 1 | 2017 | 176 | 0.030 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2016 | 28 | 0.030 |
Why?
| | Nutritional Sciences | 1 | 2017 | 37 | 0.030 |
Why?
| | Protective Factors | 1 | 2017 | 87 | 0.030 |
Why?
| | Transgenes | 1 | 2017 | 170 | 0.030 |
Why?
| | Protein Binding | 1 | 2022 | 1896 | 0.030 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2000 | 584 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2017 | 182 | 0.030 |
Why?
| | Probability | 1 | 2017 | 291 | 0.030 |
Why?
| | Drug Dosage Calculations | 1 | 2016 | 21 | 0.030 |
Why?
| | Injections, Subcutaneous | 1 | 2016 | 134 | 0.030 |
Why?
| | Mice | 1 | 2011 | 14916 | 0.030 |
Why?
| | Mouth | 1 | 2015 | 69 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1745 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2012 | 2386 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2022 | 2763 | 0.030 |
Why?
| | Synapses | 1 | 1998 | 330 | 0.030 |
Why?
| | Calpain | 1 | 2014 | 53 | 0.030 |
Why?
| | Endoscopes | 2 | 1985 | 18 | 0.030 |
Why?
| | Population Surveillance | 1 | 2017 | 392 | 0.030 |
Why?
| | Interleukin-13 | 1 | 2014 | 122 | 0.030 |
Why?
| | Steroids | 1 | 2014 | 145 | 0.030 |
Why?
| | Organ Specificity | 1 | 2014 | 268 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 863 | 0.030 |
Why?
| | Public Opinion | 1 | 1993 | 59 | 0.030 |
Why?
| | Liver Transplantation | 1 | 2000 | 706 | 0.030 |
Why?
| | Incidence | 1 | 2019 | 2312 | 0.030 |
Why?
| | Eosinophil Granule Proteins | 1 | 2012 | 20 | 0.030 |
Why?
| | Haplotypes | 1 | 2014 | 453 | 0.030 |
Why?
| | Lysophospholipase | 1 | 2012 | 10 | 0.030 |
Why?
| | Biomedical Research | 1 | 2018 | 585 | 0.030 |
Why?
| | Mass Screening | 1 | 2019 | 1003 | 0.030 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2012 | 15 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 680 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2022 | 2127 | 0.020 |
Why?
| | Forecasting | 1 | 1994 | 331 | 0.020 |
Why?
| | Diet Surveys | 1 | 2012 | 78 | 0.020 |
Why?
| | Mucous Membrane | 1 | 2012 | 108 | 0.020 |
Why?
| | Interprofessional Relations | 1 | 1994 | 249 | 0.020 |
Why?
| | Movement | 1 | 2014 | 244 | 0.020 |
Why?
| | Range of Motion, Articular | 1 | 2014 | 351 | 0.020 |
Why?
| | Models, Genetic | 1 | 2014 | 565 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 3350 | 0.020 |
Why?
| | Specimen Handling | 1 | 2012 | 156 | 0.020 |
Why?
| | Up-Regulation | 1 | 2014 | 812 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 2014 | 667 | 0.020 |
Why?
| | Age of Onset | 1 | 2012 | 448 | 0.020 |
Why?
| | Glycoproteins | 1 | 2012 | 304 | 0.020 |
Why?
| | Professional Role | 1 | 2012 | 150 | 0.020 |
Why?
| | Aged, 80 and over | 4 | 2010 | 6350 | 0.020 |
Why?
| | Joint Commission on Accreditation of Healthcare Organizations | 1 | 1990 | 7 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2012 | 623 | 0.020 |
Why?
| | Gallbladder Neoplasms | 1 | 2010 | 11 | 0.020 |
Why?
| | Comorbidity | 1 | 2015 | 1449 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2020 | 4409 | 0.020 |
Why?
| | Midazolam | 1 | 1990 | 43 | 0.020 |
Why?
| | Neurons | 1 | 1998 | 1281 | 0.020 |
Why?
| | Anesthesiology | 1 | 1990 | 35 | 0.020 |
Why?
| | Cholangiocarcinoma | 1 | 2010 | 38 | 0.020 |
Why?
| | Digestive System | 1 | 1989 | 27 | 0.020 |
Why?
| | Citric Acid | 1 | 1990 | 30 | 0.020 |
Why?
| | Bile Duct Neoplasms | 1 | 2010 | 56 | 0.020 |
Why?
| | Computer Simulation | 1 | 2014 | 878 | 0.020 |
Why?
| | Endocarditis, Bacterial | 1 | 1989 | 36 | 0.020 |
Why?
| | Health Status | 1 | 2014 | 723 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 208 | 0.020 |
Why?
| | Genetic Variation | 1 | 2014 | 876 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1774 | 0.020 |
Why?
| | Anxiety | 1 | 2015 | 842 | 0.020 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 1 | 1988 | 14 | 0.020 |
Why?
| | Social Support | 1 | 2012 | 528 | 0.020 |
Why?
| | Pneumoperitoneum | 1 | 1988 | 11 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2014 | 1197 | 0.020 |
Why?
| | Cell Movement | 1 | 2012 | 867 | 0.020 |
Why?
| | Electrocoagulation | 1 | 1987 | 38 | 0.020 |
Why?
| | Gastrostomy | 1 | 1988 | 89 | 0.020 |
Why?
| | Pediatrics | 1 | 2015 | 983 | 0.020 |
Why?
| | Stress, Psychological | 1 | 2015 | 944 | 0.020 |
Why?
| | Parents | 1 | 2015 | 1190 | 0.020 |
Why?
| | Electrocardiography | 1 | 1990 | 562 | 0.020 |
Why?
| | Duodenal Ulcer | 1 | 1985 | 10 | 0.020 |
Why?
| | Survival Rate | 1 | 2010 | 1642 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2012 | 763 | 0.020 |
Why?
| | Drug Design | 1 | 2006 | 151 | 0.020 |
Why?
| | Genetic Markers | 1 | 2006 | 321 | 0.020 |
Why?
| | Arteriovenous Malformations | 1 | 1985 | 24 | 0.020 |
Why?
| | Hemostatic Techniques | 1 | 1985 | 39 | 0.020 |
Why?
| | Stomach Neoplasms | 1 | 1985 | 65 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 1985 | 168 | 0.020 |
Why?
| | Random Allocation | 1 | 1985 | 335 | 0.010 |
Why?
| | Electrolytes | 1 | 1984 | 55 | 0.010 |
Why?
| | Streptococcal Infections | 1 | 1985 | 127 | 0.010 |
Why?
| | Colorectal Neoplasms | 1 | 2010 | 621 | 0.010 |
Why?
| | Quinidine | 1 | 1983 | 6 | 0.010 |
Why?
| | Pancreatic Neoplasms | 1 | 2010 | 732 | 0.010 |
Why?
| | Tablets | 1 | 1983 | 36 | 0.010 |
Why?
| | Colonic Diseases | 1 | 1982 | 25 | 0.010 |
Why?
| | Rectal Neoplasms | 1 | 1982 | 121 | 0.010 |
Why?
| | Dogs | 1 | 1982 | 334 | 0.010 |
Why?
| | Granulation Tissue | 1 | 2000 | 6 | 0.010 |
Why?
| | Foreign-Body Reaction | 1 | 2000 | 22 | 0.010 |
Why?
| | Aspirin | 1 | 1983 | 324 | 0.010 |
Why?
| | Pruritus | 1 | 2000 | 60 | 0.010 |
Why?
| | Equipment Failure Analysis | 1 | 2000 | 132 | 0.010 |
Why?
| | Axonal Transport | 1 | 1998 | 21 | 0.010 |
Why?
| | Fibrosis | 1 | 2000 | 453 | 0.010 |
Why?
| | Neuropeptides | 1 | 1998 | 65 | 0.010 |
Why?
| | Neurons, Afferent | 1 | 1998 | 85 | 0.010 |
Why?
| | Tracheoesophageal Fistula | 1 | 1997 | 32 | 0.010 |
Why?
| | Biocompatible Materials | 1 | 2000 | 369 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2000 | 1176 | 0.010 |
Why?
| | Brain Mapping | 1 | 1998 | 524 | 0.010 |
Why?
| | False Positive Reactions | 1 | 1988 | 108 | 0.000 |
Why?
| | Peptococcus | 1 | 1985 | 1 | 0.000 |
Why?
| | Radiography | 1 | 1988 | 811 | 0.000 |
Why?
| | Clinical Trials as Topic | 1 | 1987 | 935 | 0.000 |
Why?
| | Drinking | 1 | 1983 | 33 | 0.000 |
Why?
| | Pilot Projects | 1 | 1987 | 1370 | 0.000 |
Why?
| | Deglutition | 1 | 1983 | 58 | 0.000 |
Why?
| | Esophagitis | 1 | 1983 | 65 | 0.000 |
Why?
|
|
Fleischer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|